Apitope News

Latest Press Releases

Apitope to Present at Bio€quity Europe in May 2016

May 9, 2016

Cardiff, UK and Hasselt, Belgium: 9 May 2016 − Apitope, the drug discovery and development company focused on treating the underlying cause of autoimmune diseases, today announces that Dr Keith Martin, CEO of Apitope, is scheduled to present at Bio€quity Europe on Tuesday, 10 May 2016 at 2.20 pm CET at the Scandic Hotel, Copenhagen,…

Details

Apitope wins prize for presentation at the European Association for Haemophilia and Associated Disorders

March 9, 2016

Apitope wins prize for presentation at the European Association for Haemophilia and Associated Disorders (EAHAD) conference in Malmo, 9th February 2016. Apitope’s research director, Dr Lotta Jansson presented “treatment of FVIII inhibitors by prevention of their formation using pan DR binding ATX-F98-117: preclinical efficacy in humanized transgenic mice.”

Details

Apitope Raises €12 Million in Series B Funding to Progress Treatments for Autoimmune Diseases

September 29, 2015

Cardiff, UK and Hasselt, Belgium: 29 September 2015 − Apitope, the drug discovery and development company focused on treating the underlying cause of autoimmune diseases, today announces it has successfully raised €12 million in a Series B financing. The round was led by new investor Wales Life Sciences Fund. Current investors Vesalius Biocapital, LRM, PMV and Wyvern also participated in the round. Existing shareholders include the Wellcome Trust. Brenig Preest, Wales Life Sciences Fund, will join the Apitope board.

Details

Apitope Announces Completion of Enrolment in Phase IIA Clinical Trial of ATX-MS-1467 in Relapsing Multiple Sclerosis

August 6, 2015

Bristol, UK and Hasselt, Belgium – 6th August 2015 − Apitope, the drug discovery and development company focused on treating the underlying cause of autoimmune diseases, today announced that its partner, Merck Serono, has completed patient enrolment for the Phase IIa study of ATX-MS-1467 (also known as M2736), an investigational immune-tolerising agent. It is currently…

Details

FDA Grants Orphan Status for ATX-F8-117 for the treatment of Haemophilia A patients in the US

June 9, 2015

Prevention or treatment of haemophilia A patients with inhibitors or at risk of developing inhibitors to Factor VIII Diepenbeek, Belgium – 09 June 2015 – Apitope, the drug discovery and development company focused on disease-modifying treatments that reinstate immune tolerance, announced today that pre-clinical product candidate ATX-F8-117 has been granted Orphan Drug Status by the…

Details

Posters presented by Apitope at Knowledge for Growth available in full

May 26, 2015

Bristol, UK and Hasselt, Belgium – 26th May 2015 – Apitope’s research director, Dr. Lotta Jansson and scientist, Dr. Kathleen Vrolix have presented posters titled: “Prevention of FVIII inhibitor formation by ATX-F8-117 in humanized HLA-DRB1*1501 mice” and “Antigen-specific peptide therapy prevents formation of TSHR antibodies in HLA-DR transgenic mice” during Knowledge for Growth (see event announcement).…

Details